HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Lyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Lyell Immunopharma Q1 EPS $(1.10) Beats $(2.19) Estimate, Sales $2.000K Miss $4.400K Estimate
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
A First Look At Lyell Immunopharma
Needham Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet
Lyell Immunopharma shares are trading lower after the company reported worse-than-expected Q4 financial results.
Lyell Immunopharma: Q4 Earnings Snapshot
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Lyell Immunopharma Q4 EPS $(7.68) Misses $(2.55) Estimate, Sales $6.000K Miss $20.330K Estimate
Lyell Immunopharma shares are trading higher after the company announced closing of additional $50 million tranche of $100 million equity private placement and the appointment of Smital Shah as Chief Financial and Business Officer.
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Citizens Initiates Coverage On Lyell Immunopharma with Market Outperform Rating, Announces Price Target of $34
Lyell Immunopharma Secures Additional $50M From Private Placement After CAR-T Trial Milestone; Appoints Smital Shah As CFO
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.